AR030913A1 - A COMPOUND DERIVED FROM INDOLINA, ITS USE, A PROCEDURE TO PREPARE IT, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND A PROCEDURE TO PREPARE SUCH COMPOSITION - Google Patents
A COMPOUND DERIVED FROM INDOLINA, ITS USE, A PROCEDURE TO PREPARE IT, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND A PROCEDURE TO PREPARE SUCH COMPOSITIONInfo
- Publication number
- AR030913A1 AR030913A1 ARP000104121A ARP000104121A AR030913A1 AR 030913 A1 AR030913 A1 AR 030913A1 AR P000104121 A ARP000104121 A AR P000104121A AR P000104121 A ARP000104121 A AR P000104121A AR 030913 A1 AR030913 A1 AR 030913A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- prepare
- procedure
- hydrogen
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compuestos derivados de indolina de formula (1) en el que : R1 y R2 se seleccionan independientemente de hidrogeno y alquilo, R3 es alquilo, R4 y R5 se seleccionan de hidrogeno y alquilo, R6 y R7 se seleccionan independientemente de hidrogeno, halogeno, hidroxi, alquilo, arilo, amino, alquilamino, dialquilamino, alcoxi, ariloxi, alquiltio, alquilsulfoxilo, alquilsulfonilo, nitro, carbonitrilo, carboalcoxi, carboariloxi, y carboxilo, y A es un anillo de 5 a 6 eslabones que contiene opcionalmente uno o más heteroátomos, estando saturados o insaturados los átomos del anillo A distintos de los átomos de carbono insaturados del anillo de fenilo al que está condensado el anillo A; y las sales, compuesto de adicion y promedicamentos farmacéuticamente aceptables de estos; y el uso de estos en terapia, particularmente como agonistas o antagonistas de un receptor de 5-HT, particularmente en receptor de 5-HT2c, por ejemplo en el tratamiento de trastornos del sistema nervioso central, dano al sistema nervioso central, trastornos cardiovasculares, trastornos gastrointestinales, diabetes insípida y apnea del sueno y particularmente para el tratamiento de la obesidad.Indoline-derived compounds of formula (1) in which: R1 and R2 are independently selected from hydrogen and alkyl, R3 is alkyl, R4 and R5 are selected from hydrogen and alkyl, R6 and R7 are independently selected from hydrogen, halogen, hydroxy , alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, alkylsulfonyl, nitro, carbonitrile, carboalkoxy, carboaryloxy, and carboxyl, and A is a 5 to 6 link ring optionally containing one or more heteroatoms, the atoms of ring A other than the unsaturated carbon atoms of the phenyl ring to which ring A is condensed are saturated or unsaturated; and salts, compound of pharmaceutically acceptable addition and averages thereof; and the use of these in therapy, particularly as agonists or antagonists of a 5-HT receptor, particularly in 5-HT2c receptor, for example in the treatment of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus and sleep apnea and particularly for the treatment of obesity.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9918965.6A GB9918965D0 (en) | 1999-08-11 | 1999-08-11 | Chemical compounds xxi |
Publications (1)
Publication Number | Publication Date |
---|---|
AR030913A1 true AR030913A1 (en) | 2003-09-03 |
Family
ID=10858983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000104121A AR030913A1 (en) | 1999-08-11 | 2000-08-10 | A COMPOUND DERIVED FROM INDOLINA, ITS USE, A PROCEDURE TO PREPARE IT, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND A PROCEDURE TO PREPARE SUCH COMPOSITION |
Country Status (19)
Country | Link |
---|---|
US (10) | US6962939B1 (en) |
EP (1) | EP1202964B1 (en) |
JP (1) | JP2003507366A (en) |
KR (2) | KR20020015077A (en) |
CN (1) | CN1167681C (en) |
AR (1) | AR030913A1 (en) |
AT (1) | ATE306470T1 (en) |
AU (1) | AU774337B2 (en) |
BR (1) | BR0013314A (en) |
CA (1) | CA2377637A1 (en) |
DE (1) | DE60023146T2 (en) |
ES (1) | ES2250167T3 (en) |
GB (1) | GB9918965D0 (en) |
MX (1) | MXPA01013252A (en) |
PE (1) | PE20010575A1 (en) |
TR (1) | TR200200351T2 (en) |
UY (1) | UY26290A1 (en) |
WO (1) | WO2001012602A1 (en) |
ZA (1) | ZA200110218B (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9918965D0 (en) * | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxi |
SE0004245D0 (en) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
AU1529402A (en) | 2000-11-20 | 2002-05-27 | Biovitrum Ab | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
WO2002074746A1 (en) * | 2001-03-16 | 2002-09-26 | Yamanouchi Pharmaceutical Co., Ltd. | Benzazepine derivatives |
BR0211140A (en) * | 2001-07-13 | 2005-10-25 | Upjohn Co | Compounds and compositions of hexahydroazepine (4,5-g) indoles and indolines as 5-ht receptor binders |
TWI312781B (en) | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
TW200307540A (en) * | 2002-04-25 | 2003-12-16 | Wyeth Corp | [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents |
TW200307682A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
DE60330864D1 (en) | 2002-06-19 | 2010-02-25 | Biovitrum Ab Publ | NEW CONNECTIONS, THEIR USE AND MANUFACTURE |
CL2004000826A1 (en) | 2003-04-25 | 2005-03-04 | Pfizer | USE OF AN AGONIST FOR THE 5-HT2C RECEPTOR TO PREPARE A USEFUL MEDICINAL PRODUCT IN THE TREATMENT OF URINARY INCONTINENCE CAUSED BY STRESS, WITH THE CONDITION THAT THE AGONIST IS NOT 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2- PIRIDINIL] PIPERAZINA (ORG-129 |
GB0314967D0 (en) | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
AR046890A1 (en) * | 2003-12-15 | 2005-12-28 | Alcon Inc | [1,4] OXAZINO [2,3-G] SUBSTITUTED INDAZOLS FOR THE TREATMENT OF GLAUCOMA. |
WO2006022420A1 (en) | 2004-08-25 | 2006-03-02 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
GT200500317A (en) | 2004-11-05 | 2006-10-27 | PROCESS TO PREPARE QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED FROM THEM | |
US7425572B2 (en) | 2004-12-08 | 2008-09-16 | Alcon, Inc. | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma |
AR054849A1 (en) | 2005-07-26 | 2007-07-18 | Wyeth Corp | DIAZEPINOQUINOLINAS, SYNTHESIS OF THE SAME, AND INTERMEDIARIES TO OBTAIN THEM |
US20090203750A1 (en) * | 2005-08-24 | 2009-08-13 | Alan Kozikowski | 5-HT2C Receptor Agonists as Anorectic Agents |
EP2727585A1 (en) | 2006-05-16 | 2014-05-07 | Takeda Pharmaceutical Company Limited | In-vivo screening method |
DE102006033114A1 (en) * | 2006-07-18 | 2008-01-24 | Grünenthal GmbH | Spirocyclic azaindole derivatives |
EP2789338A3 (en) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Condensed pyridine derivate and use thereof |
WO2011071136A1 (en) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | Therapeutic agent for fibromyalgia |
WO2011097336A2 (en) | 2010-02-04 | 2011-08-11 | The Board Of Trustees Of The University Of Illinois | Highly selective 5-ht(2c) receptor agonists having antagonist activity at the 5-ht(2b) receptor |
ES2889876T3 (en) | 2015-01-29 | 2022-01-14 | Univ Illinois | Cyclopropylmethanamines as selective 5-HT(2C) receptor agonists |
WO2018151239A1 (en) * | 2017-02-17 | 2018-08-23 | 第一三共株式会社 | 3, 6-DIHYDRO-2H-FURO[2, 3-e]INDOLE COMPOUND |
WO2018151240A1 (en) * | 2017-02-17 | 2018-08-23 | 第一三共株式会社 | 3,6,7,8-TETRAHYDROCYCLOPENTA[e]INDOLE COMPOUND |
EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | Therapeutic agent for stress urinary incontinence and fecal incontinence |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2541211A (en) | 1948-10-15 | 1951-02-13 | Searle & Co | Tertiary-aminoalkyl-tetrahydrocarbazoles |
US2687414A (en) | 1948-11-26 | 1954-08-24 | Searle & Co | Method for producing aromatic aminoalkyl amines |
DE930988C (en) | 1953-01-01 | 1955-07-28 | Bayer Ag | Process for the preparation of basic alkylated tetrahydrocarbazoles or indoles |
US3329571A (en) | 1961-10-24 | 1967-07-04 | American Home Prod | Methods for treating depression |
US3142678A (en) | 1962-01-09 | 1964-07-28 | American Home Prod | Amino substituted penthienoindoles |
TW270114B (en) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
TW334423B (en) | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
GB9326192D0 (en) * | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
TW403738B (en) | 1994-08-12 | 2000-09-01 | Hoffmann La Roche | Tricyclic pyrazole derivatives |
FR2742047B1 (en) * | 1995-12-06 | 1998-01-16 | Oreal | KERATINIC FIBER DYEING COMPOSITIONS CONTAINING N-SUBSTITUTED DERIVATIVES OF 4-HYDROXY INDOLINE, NEW DERIVATIVES, THEIR SYNTHESIS METHOD, THEIR USE FOR DYEING, AND THE DYEING METHOD |
AU5343298A (en) | 1997-01-13 | 1998-08-03 | Yamanouchi Pharmaceutical Co., Ltd. | 5-ht2c receptor agonists and aminoalkylindazole derivatives |
AU727654B2 (en) * | 1997-06-13 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrazole derivative |
GB9819019D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
GB9819033D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
GB9819035D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
GB9918962D0 (en) | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxii |
GB9918965D0 (en) * | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxi |
-
1999
- 1999-08-11 GB GBGB9918965.6A patent/GB9918965D0/en not_active Ceased
-
2000
- 2000-08-04 CN CNB008115168A patent/CN1167681C/en not_active Expired - Fee Related
- 2000-08-04 AU AU64554/00A patent/AU774337B2/en not_active Ceased
- 2000-08-04 DE DE60023146T patent/DE60023146T2/en not_active Expired - Fee Related
- 2000-08-04 EP EP00951696A patent/EP1202964B1/en not_active Expired - Lifetime
- 2000-08-04 TR TR2002/00351T patent/TR200200351T2/en unknown
- 2000-08-04 JP JP2001517500A patent/JP2003507366A/en not_active Abandoned
- 2000-08-04 WO PCT/GB2000/003008 patent/WO2001012602A1/en active IP Right Grant
- 2000-08-04 MX MXPA01013252A patent/MXPA01013252A/en active IP Right Grant
- 2000-08-04 ES ES00951696T patent/ES2250167T3/en not_active Expired - Lifetime
- 2000-08-04 US US10/009,567 patent/US6962939B1/en not_active Expired - Fee Related
- 2000-08-04 KR KR1020027001107A patent/KR20020015077A/en active IP Right Grant
- 2000-08-04 BR BR0013314-0A patent/BR0013314A/en not_active IP Right Cessation
- 2000-08-04 CA CA002377637A patent/CA2377637A1/en not_active Abandoned
- 2000-08-04 AT AT00951696T patent/ATE306470T1/en not_active IP Right Cessation
- 2000-08-04 KR KR1020077014953A patent/KR20070086814A/en not_active Application Discontinuation
- 2000-08-09 PE PE2000000808A patent/PE20010575A1/en not_active Application Discontinuation
- 2000-08-10 AR ARP000104121A patent/AR030913A1/en active IP Right Grant
- 2000-08-11 UY UY26290A patent/UY26290A1/en not_active Application Discontinuation
-
2001
- 2001-12-12 ZA ZA200110218A patent/ZA200110218B/en unknown
-
2005
- 2005-04-29 US US11/117,460 patent/US7166632B2/en not_active Expired - Fee Related
- 2005-04-29 US US11/117,488 patent/US7173056B2/en not_active Expired - Fee Related
- 2005-04-29 US US11/117,459 patent/US7166613B2/en not_active Expired - Fee Related
-
2006
- 2006-12-12 US US11/637,036 patent/US7323486B2/en not_active Expired - Fee Related
- 2006-12-12 US US11/637,042 patent/US7323473B2/en not_active Expired - Fee Related
- 2006-12-12 US US11/637,082 patent/US7323487B2/en not_active Expired - Fee Related
-
2007
- 2007-11-21 US US11/984,735 patent/US20080114018A1/en not_active Abandoned
- 2007-11-21 US US11/984,734 patent/US20080125455A1/en not_active Abandoned
- 2007-12-04 US US11/987,774 patent/US20080090858A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR030913A1 (en) | A COMPOUND DERIVED FROM INDOLINA, ITS USE, A PROCEDURE TO PREPARE IT, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND A PROCEDURE TO PREPARE SUCH COMPOSITION | |
AR037222A1 (en) | A DERIVATIVE OF INDOL, ITS USE, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND A PROCEDURE TO PREPARE SUCH COMPOSITION | |
PE20040937A1 (en) | DERIVATIVES OF PYRIDAZIN-3 (2H) -ONE AS INHIBITORS OF PHOSPHODIESTERASE-4 (PDE 4) | |
PE20060531A1 (en) | DERIVATIVES OF PYRIDAZIN-3- (2H) -ONE AS INHIBITORS OF PHOSPHODIESTERASE 4 | |
PE20001483A1 (en) | OXAMIC ACIDS AND DERIVATIVES AS LIGANDS OF THYROID RECEPTORS | |
PE20030039A1 (en) | INDOLE DERIVATIVES WITH AFFINITY FOR THE 5-HT6 RECEPTOR | |
TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
MXPA05009359A (en) | 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators. | |
HUP0000914A2 (en) | Atropisomers of 3-aryl-4(3h)-quinazolinones and pharmaceutical compositions containing them | |
PE20081316A1 (en) | HETEROCYCLIC COMPOUNDS THAT MODULATE THE ACTIVITY OF STEROIL-CoA-DESATURASE | |
MA31419B1 (en) | PYRIDINE DERIVATIVES | |
IL197642A (en) | Heterocyclic derivatives and uses thereof in the preparation of pharmaceutical compositions for treating opioid receptor related disorders | |
DK0607164T3 (en) | Condensed tricyclic nitrogen-containing heterocyclic compounds as substance P receptor antagonists | |
EA200702058A1 (en) | NEW PHARMACEUTICAL COMPOUNDS | |
PE20060630A1 (en) | SUBSTITUTE AMIDES OF HAVE-PYRROLCARBOXYLIC ACID, AMIDES OF PYRROLOTIAZOL-CARBOXYL ACID AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE IE | |
PE20050726A1 (en) | DERIVATIVES OF 1-SULFONILINDOLES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINES | |
PE20021043A1 (en) | PIRAZINE [1,2-a] INDOLE DERIVATIVES AS 5HT2 RECEPTOR AGONISTS | |
PE20040763A1 (en) | DERIVATIVES OF AMINOALCOXYINDOLS AS BINDERS OF 5-HT6 RECEPTORS | |
MX2007011280A (en) | Dipyrazoles as central nervous system agents. | |
AR035451A1 (en) | DERIVATIVES OF BETA-CARBOLINA, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DEPRESSION, ANXIETY AND BIPOLAR DISORDERS, A PHARMACEUTICAL COMPOSITION AND A COMBINATION. | |
PE20080941A1 (en) | TRICYCLE COMPOUNDS AS MELATONIN RECEPTOR AGONISTS | |
EA200300915A1 (en) | ISOXASOLINE DERIVATIVES AS ANTIDEPRESSANTS | |
PE20050333A1 (en) | DERIVATIVES OF 4-INDOLYLSUFONAMIDES AS MODULATORS OF THE SEROTONIN RECEPTOR (5-HT6) | |
ECSP003613A (en) | CHEMICAL COMPOUNDS XXI | |
CO5170464A1 (en) | DERIVATIVES OF 1-TRIFLUOROMETIL-4-HIDROXI-7-PIPERIDINIL- AMINOMETILCROMANO |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |